Excision repair cross-complementation group 1 (ERCC1) status and lung cancer outcomes: a meta-analysis of published studies and recommendations. (Q34055535)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Excision repair cross-complementation group 1 (ERCC1) status and lung cancer outcomes: a meta-analysis of published studies and recommendations.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22022380%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

0 references

Excision repair cross-complementation group 1 (ERCC1) status and lung cancer outcomes: a meta-analysis of published studies and recommendations (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22022380%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference

based on heuristic

inferred from title

Richard A Hubner

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22022380%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Lucinda J. Billingham

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22022380%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22022380%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

author name string

Richard D Riley

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22022380%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

language of work or name

0 references

publication date

14 October 2011

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22022380%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22022380%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22022380%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22022380%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

e25164

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22022380%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

copyright license

Creative Commons Attribution 4.0 International

14 October 2011

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Immunodetection of DNA repair endonuclease ERCC1-XPF in human tissue.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194810

5 July 2018

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194810

5 July 2018

Different impact of excision repair cross-complementation group 1 on survival in male and female patients with inoperable non-small-cell lung cancer treated with carboplatin and gemcitabine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194810

5 July 2018

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194810

5 July 2018

Cancer statistics, 2009

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194810

5 July 2018

DNA repair pathways as targets for cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194810

5 July 2018

BRCA1: a novel prognostic factor in resected non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194810

5 July 2018

ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194810

5 July 2018

Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194810

5 July 2018

Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194810

5 July 2018

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194810

5 July 2018

Evaluation of the quality of prognosis studies in systematic reviews

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194810

5 July 2018

Time and chemotherapy treatment trends in the treatment of elderly patients (age >/=70 years) with small cell lung cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194810

5 July 2018

Erlotinib in lung cancer - molecular and clinical predictors of outcome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194810

5 July 2018

ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194810

5 July 2018

Reporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the future

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194810

5 July 2018

DNA damage and repair

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194810

5 July 2018

Smoking-related DNA and protein adducts in human tissues.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194810

5 July 2018

Aggregate data meta-analysis with time-to-event outcomes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194810

5 July 2018

Quantifying heterogeneity in a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194810

5 July 2018

Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194810

5 July 2018

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194810

5 July 2018

Review of survival analyses published in cancer journals

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194810

5 July 2018

Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0025164

21 January 2018

Interpretation of random effects meta-analyses.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0025164

21 January 2018

A re-evaluation of random-effects meta-analysis.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0025164

21 January 2018

ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0025164

21 January 2018

Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0025164

21 January 2018

XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0025164

21 January 2018

Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0025164

21 January 2018

Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0025164

21 January 2018

Excision repair cross complementing-1 and topoisomerase IIalpha gene expression in small-cell lung cancer patients treated with platinum and etoposide: a retrospective study

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0025164

21 January 2018

Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0025164

21 January 2018

ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0025164

21 January 2018

ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0025164

21 January 2018

Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0025164

21 January 2018

DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0025164

21 January 2018

Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0025164

21 January 2018

Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0025164

21 January 2018

Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0025164

21 January 2018

Expression of Bcl-2 predicts outcome in locally advanced non-small cell lung cancer patients treated with cisplatin-based concurrent chemoradiotherapy.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0025164

21 January 2018

Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0025164

21 January 2018

Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194810

28 October 2018

Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194810

28 October 2018

ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0025164

21 January 2018

Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non–Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0025164

21 January 2018

ERCC1 and non-small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22022380

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22022380

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22022380

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1371/JOURNAL.PONE.0025164

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22022380%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

2011PLoSO...625164H

0 references

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22022380%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22022380%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34055535&oldid=1966821466"